Impact Factor
4.60
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
10.09
2,342 total citations
h5-index
51
h5 depth signal
Cited share
96.1%
246 of 256
Total citations
2,342
Citation footprint
Metric signal
9.14
External metric anchor
Self-citation
4.1%
97 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
771
United States
120
India
109
South Korea
34
Germany
28
Citing Fields of Research
Cancer, Autophagy & Apoptosis
678
Immunology
230
Cell Biology
150
Cancer & Development
115
Oncology
99
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,325
Articles tracked across the journal lifetime
Indexed publication set
256
246 cited publications
Last 12 months
251
22.8 publications/month
Open access share
15.5%
39 OA publications in the last year
Leading citing country
China
771 citing publications
Leading citing field
Cancer, Autophagy & Apoptosis
678 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v5n1, Feb. 2000-
v5n1, Feb. 2000-
Active Coverage
Research Focus & Classification
Indexed Subjects
Cancer, Autophagy & Apoptosis
Immunology
Cancer & Development
Noncoding RNA
Oncology
Broad Categories
Cell Biology
Cancer, Autophagy & Apoptosis
Immunology
Noncoding RNA
Cancer & Development
MeSH Descriptors
Apoptosis
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1007/s10495-026-02463-3
Open DOI
Apolipoprotein A1 attenuates epirubicin-induced cardiotoxicity with GPX4-linked ferroptosis-defense modulation
Anthracycline-induced cardiotoxicity (AIC), in which ferroptosis-related cardiomyocyte injury has been implicated, remains a major challenge in oncology. This study investigates the therapeutic potential of an apolipoprotein A1 (ApoA1) m...
02
03
04
05
DOI 10.1007/s10495-026-02440-w
Open DOI
Necroptosis as a key player in cervical cancer progression and management: a systematic review and transcriptomic cross-study consensus analysis
Immunotherapy has improved outcomes for a subset of patients with locally advanced cervical cancer. However, many tumors remain immunologically “cold” and fail to respond. Strategies that enhance tumor immunogenicity are therefore of inc...
06
DOI 10.1007/s10495-026-02458-0
Open DOI
Shedding light on the cancer cell death mechanism in photodynamic therapy
07
08
DOI 10.1007/s10495-026-02460-6
Open DOI
CAF-derived GLG1 drives bladder cancer growth and apoptosis resistance
09
DOI 10.1007/s10495-026-02451-7
Open DOI
The ferroptosis–cuproptosis crosstalk in hematological malignancies: multi-omics insights into gene-regulated cell death and emerging therapeutic opportunities
The broadening field of regulated cell death (RCD) has shown a complex, intertwined web of pathways that are not confined to apoptosis but also to ferroptosis, cuproptosis, necroptosis, and other non-canonical mechanisms, especially in h...
10
DOI 10.1007/s10495-026-02455-3
Open DOI
Anastasis: an unwelcome guest in cancer therapy
Anastasis is a newly identified cellular recovery process that enables cells to regain viability after progressing into execution-phase apoptosis. In cancer, this process may allow tumor cells to survive transient cytotoxic stress and su...
Bibliographical & Catalog Notes
Description based on: Vol. 2, issue 2 (Apr. 1997); title from cover.
Also issued online.